期刊
COLLOIDS AND SURFACES B-BIOINTERFACES
卷 87, 期 2, 页码 319-325出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.colsurfb.2011.05.037
关键词
Oridonin nanosuspension; Cytotoxicity; Anti-tumor activity; SMMC-7721 cells; H22 cells
资金
- National Basic Research Program of China (973 Program) [2009CB930300]
Purpose: The aim of the present study was to evaluate both the in vitro and in vivo antitumor activity of an oridonin nanosuspension (ORI-N) relative to efficacy of bulk oridonin delivery. Methods: ORI-N with a particle size of 897.2 +/- 14.2 nm and a zeta potential of -21.8 +/- 0.8 mV was prepared by the high-pressure homogenization (HPH) technique. The in vitro cytotoxicity of ORI-N against SMMC-7721 cells was evaluated by MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay, the effects of ORI-N on cell cycle and cell apoptosis was analyzed by flow cytometry; the in vivo anti-tumor activity was observed in H22 tumor bearing mice. Results: ORI-N effectively inhibited the proliferation of SMMC-7721 cells. Flow cytometric analysis demonstrated that ORI-N arrested SMMC-7721 cells in the G2/M cycle, and furthermore, that ORI-N induced a higher apoptotic rate than the bulk ORI solution. In vivo studies ORI-N also showed higher antitumor efficacy as measured by reduced tumor volume and tumor weight, as well as lower toxicity in H22 solid tumor bearing mice compared to free ORI at the same concentration. Conclusions: These results suggest that the delivery of ORI-N as a nanosuspension is a promising approach for treating tumors. (C) 2011 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据